[go: up one dir, main page]

MX2017013171A - Conjugados anticuerpo-farmaco de sitio especifico. - Google Patents

Conjugados anticuerpo-farmaco de sitio especifico.

Info

Publication number
MX2017013171A
MX2017013171A MX2017013171A MX2017013171A MX2017013171A MX 2017013171 A MX2017013171 A MX 2017013171A MX 2017013171 A MX2017013171 A MX 2017013171A MX 2017013171 A MX2017013171 A MX 2017013171A MX 2017013171 A MX2017013171 A MX 2017013171A
Authority
MX
Mexico
Prior art keywords
site
specific antibody
drug conjugates
antibody
amino acid
Prior art date
Application number
MX2017013171A
Other languages
English (en)
Inventor
Wilson Howard Philip
Hendrikus Cornelis Van Berkel Patricius
Original Assignee
Adc Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adc Therapeutics S A filed Critical Adc Therapeutics S A
Publication of MX2017013171A publication Critical patent/MX2017013171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen conjugados anticuerpo-fármaco de sitio específico, en particular conjugados que comprenden pirrolobenzodiazepinas (PBD) que tienen un grupo protector lábil en forma de un ligador. El sitio de conjugación, junto con la modificación del resto de anticuerpo, permite una mejora en la seguridad y la eficacia del ADC.
MX2017013171A 2015-04-15 2016-04-15 Conjugados anticuerpo-farmaco de sitio especifico. MX2017013171A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506394.4A GB201506394D0 (en) 2015-04-15 2015-04-15 Site-specific antibody-drug conjugates
PCT/EP2016/058372 WO2016166300A1 (en) 2015-04-15 2016-04-15 Site-specific antibody-drug conjugates

Publications (1)

Publication Number Publication Date
MX2017013171A true MX2017013171A (es) 2018-01-16

Family

ID=53333826

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013171A MX2017013171A (es) 2015-04-15 2016-04-15 Conjugados anticuerpo-farmaco de sitio especifico.

Country Status (11)

Country Link
US (1) US20180117172A1 (es)
EP (1) EP3283119A1 (es)
JP (1) JP2018512439A (es)
KR (1) KR20170137786A (es)
CN (1) CN107548306A (es)
AU (1) AU2016247504A1 (es)
BR (1) BR112017022252A2 (es)
CA (1) CA2982516A1 (es)
GB (1) GB201506394D0 (es)
MX (1) MX2017013171A (es)
WO (1) WO2016166300A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201602363D0 (en) * 2016-02-10 2016-03-23 Adc Therapeutics Sa And Medimmune Ltd Pyrrolobenzodiazepine conjugates
MX375568B (es) 2017-02-08 2025-03-06 Medimmune Ltd Conjugados de pirrolobenzodiazepinas y anticuerpos
AU2018253950A1 (en) 2017-04-20 2019-09-19 Adc Therapeutics Sa Combination therapy with an anti-CD25 antibody-drug conjugate
WO2018229218A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd25 adc
CN111065638B (zh) * 2017-08-18 2021-04-09 麦迪穆有限责任公司 吡咯并苯并二氮杂䓬缀合物
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
IL286326B2 (en) 2019-03-15 2025-10-01 Medimmune Ltd Azatidobenzodiazepine dimers and conjugates containing them for use in the treatment of cancer
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005316844A1 (en) * 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
US20130330350A1 (en) * 2010-11-09 2013-12-12 Medimmune, Llc Antibody Scaffold For Homogenous Conjugation
LT2906252T (lt) * 2012-10-12 2017-09-11 Adc Therapeutics Sa Pirolobenzodiazepino-anti-her2 antikūno konjugatai
WO2014057073A1 (en) * 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
AU2014312210A1 (en) * 2013-08-28 2016-04-07 Abbvie Stemcentrx Llc Engineered anti-DLL3 conjugates and methods of use

Also Published As

Publication number Publication date
CN107548306A (zh) 2018-01-05
BR112017022252A2 (pt) 2018-07-31
JP2018512439A (ja) 2018-05-17
KR20170137786A (ko) 2017-12-13
US20180117172A1 (en) 2018-05-03
WO2016166300A1 (en) 2016-10-20
CA2982516A1 (en) 2016-10-20
AU2016247504A1 (en) 2017-10-26
EP3283119A1 (en) 2018-02-21
GB201506394D0 (en) 2015-05-27

Similar Documents

Publication Publication Date Title
MX2017013154A (es) Conjugados anticuerpo-farmaco de sitio especifico.
MX2017013171A (es) Conjugados anticuerpo-farmaco de sitio especifico.
ZA201706745B (en) Site-specific antibody-drug conjugates
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
ZA201805336B (en) Amanitin conjugates
MX2016016515A (es) Derivados de auristatina y conjugados de los mismos.
ZA201903062B (en) Amanitin antibody conjugates
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
MX2016007865A (es) Peptidos citotoxicos y conjugados de los mismos.
ZA201903667B (en) Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
CY1123525T1 (el) Μορια δεσμευσης ειδικα για asct2 και χρησεις αυτων
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
MX2024002632A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
MY206244A (en) Anti-muc1 antibody-drug conjugate
NZ752526A (en) Pyrrolobenzodiazepine conjugates
MX395142B (es) Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores.
BR112016004242A2 (pt) métodos para conjugação sítio-específica de anticorpos e composições
NZ754811A (en) Pyrrolobenzodiazepine-antibody conjugates
MX2015005124A (es) Conjugados de farmaco-proteina.
NZ703581A (en) Anti-cd70 antibody drug conjugates
WO2014134483A3 (en) Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
EA201992595A1 (ru) Усиление фармакокинетики бифункциональных хелатов и их применения
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
MA39909A (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
EA202091161A1 (ru) Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения